Download PDF
Thromb Haemost 2012; 108(02): 397-398
DOI: 10.1160/TH12-02-0121
Letters to the Editor
Schattauer GmbH

Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and diamond-blackfan-anaemia

Karolin Trautmann
1   Medical Clinic and Policlinic I, University Hospital Dresden, Germany
,
Christiane Jakob
2   Institute of Pathology, University Hospital Dresden, Germany
,
Ulrich von Grünhagen
3   Oncology Practice, Cottbus, Germany
,
Eberhard Schleyer
4   Carl-von-Basedow Clinic, Merseburg, Germany
,
Tim H. Brümmendorf
5   Department of Oncology and Hematology, University Hospital Aachen, Germany
,
Gabriele Siegert
6   Institute of Clinical Chemistry, University Hospital Dresden, Germany
,
Gerhard Ehninger
1   Medical Clinic and Policlinic I, University Hospital Dresden, Germany
,
Uwe Platzbecker
1   Medical Clinic and Policlinic I, University Hospital Dresden, Germany
› Author Affiliations
Further Information

Publication History

Received: 02 March 2012

Accepted after major revision: 07 May 2012

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Pecci A, Gresele P, Klersy C. et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116: 5832-5870.
    CrossrefPubMedGoogle Scholar
  • 2 Gröpper S, Althaus K, Najm J. et al. A patient with Fechtner syndrome successfully treated with romiplostim. Thromb Haemost 2012; 107: 590-591.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Pecci A, Barozzi S, d’Amico S. et al. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation. Thromb Haemost 2012; 107: 1188-1189.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Olnes MJ, Scheinberg P, Calvo K. et al. Eltrombopag can stimulate trilineage hematopoiesis with transfusion independence in patients with refractory severe aplastic anemia: results from a phase II trial. Blood (Annual Meeting Abstracts) 2011; 118: 54.
    PubMedGoogle Scholar
  • 5 Jenkins JM, Williams D, Deng Y. et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109: 4739-4741.
    CrossrefPubMedGoogle Scholar
  • 6 Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am 2009; 23: 261-282.
    CrossrefPubMedGoogle Scholar
  • 7 Freedman MH. Inherited Forms of Bone Marrow Failure. Hematology: Basic Principles and Practice. Elsevier; 2005
    Google Scholar
  • 8 Du HY, Pumbo E, Ivanovich J. et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 2009; 113: 309.
    PubMedGoogle Scholar
  • 9 Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Hematol 2011; 154: 161-174.
    CrossrefPubMedGoogle Scholar
  • 10 Pecci A, Malara A, Badalucco S. et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost 2009; 102: 90-96.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Nurden P, Nurden AT. Congenital disorders associated with platelet dysfuncions. Thromb Haemost 2008; 99: 253-263.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost 2009; 35: 189-203.
    Article in Thieme ConnectPubMedGoogle Scholar